Hu Kaixuan, Wang Shanqing
Plastic Surgery Department, Quzhou Kecheng Dainiel Plastic Surgery Outpatient, Quzhou City, China.
Department of Dermatology, School of Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, Shanghai City, China.
J Cosmet Dermatol. 2025 Sep;24(9):e70414. doi: 10.1111/jocd.70414.
Nasolabial folds (NLF) deepen with age, necessitating aesthetic treatments. Polycaprolactone (PCL) and poly-l-lactic acid (PLLA) are commonly used fillers. This study compares their safety and efficacy for NLF correction.
Participants aged 30-60 years were retrospectively reviewed after undergoing NLF correction with PCL (n = 65) or PLLA (n = 71) from January 2023 to December 2023. Primary outcomes included changes in the Nasolabial Fold Wrinkle Severity Rating Scale (WSRS) at baseline and 3, 6, and 12 months post-treatment. Secondary outcomes assessed patient satisfaction via the FACE-Q scale, Global Aesthetic Improvement Scale (GAIS), and safety profiles including side effects and adverse events.
At 3 months, PCL exhibited significantly greater wrinkle reduction (WSRS score: 3.08 ± 0.37) compared to PLLA (3.27 ± 0.41; p = 0.007). This trend persisted at 6 months (PCL: 2.23 ± 0.61 vs. PLLA: 2.49 ± 0.75; p = 0.03) and 12 months (PCL: 1.92 ± 0.55 vs. PLLA: 2.17 ± 0.61; p = 0.016). PCL also showed higher significant improvement rates on GAIS at 3 and 6 months. Patient satisfaction (FACE-Q) was higher in the PCL group at both 6 and 12 months (p < 0.05). Safety profiles were comparable, with no significant differences in injection site reactions or adverse events.
PCL injections demonstrated superior effectiveness in reducing NLF wrinkle severity and achieving higher patient satisfaction compared to PLLA injections over a 12-month period. Both materials exhibited comparable safety profiles, suggesting the suitability of PCL as a preferable option for NLF correction in cosmetic dermatology.
鼻唇沟会随着年龄增长而加深,因此需要进行美容治疗。聚己内酯(PCL)和聚左旋乳酸(PLLA)是常用的填充剂。本研究比较了它们矫正鼻唇沟的安全性和有效性。
回顾性分析了2023年1月至2023年12月期间接受PCL(n = 65)或PLLA(n = 71)矫正鼻唇沟治疗的30至60岁参与者。主要结局包括治疗前基线以及治疗后3、6和12个月时的鼻唇沟皱纹严重程度评分量表(WSRS)变化。次要结局通过面部质量问卷(FACE-Q)量表、整体美学改善量表(GAIS)评估患者满意度,并评估包括副作用和不良事件在内的安全性。
在3个月时,PCL组的皱纹减少程度(WSRS评分:3.08 ± 0.37)显著大于PLLA组(3.27 ± 0.41;p = 0.007)。这种趋势在6个月时持续存在(PCL组:2.23 ± 0.61,PLLA组:2.49 ± 0.75;p = 0.03),在12个月时也持续存在(PCL组:1.92 ± 0.55,PLLA组:2.17 ± 0.61;p = 0.016)。PCL在3个月和6个月时的GAIS改善率也更高。在6个月和12个月时,PCL组的患者满意度(FACE-Q)更高(p < 0.05)。安全性相当,注射部位反应或不良事件无显著差异。
在12个月的时间里,与PLLA注射相比,PCL注射在减轻鼻唇沟皱纹严重程度和提高患者满意度方面显示出更优的效果。两种材料的安全性相当,这表明PCL作为美容皮肤科矫正鼻唇沟的更优选择是合适的。